

Key Figures

All figures are given in millions of € according to the IFRS, unless otherwise specified	2021	Δ in %	2020 ⁷	2019	2018	2017
Order intake, sales revenue and earnings						
Order intake	3,664.4	53.9	2,381.0	1,543.5	1,307.3	1,162.3
Sales revenue	2,887.0	51.1	1,910.1	1,440.6	1,212.2	1,081.0
Underlying EBITDA ^{1,2}	1,033.4	70.9	604.7	421.5	342.4	294.9
Underlying EBITDA ^{1,2} as % of sales revenue	35.8	4.1pp	31.7	29.3	28.2	27.3
Net profit after non-controlling interest	414.4	23.4	335.9	234.5	208.1	161.1
Underlying net profit after non-controlling interest ³	687.8	79.2	383.8	263.0	219.3	180.4
Research and development costs	110.5	30.8	84.5	79.2	60.6	53.2
Financial data per share						
Earnings per share (in €)	4.50	23.4	3.64	2.54	2.26	1.75
Earnings per share (in €) ³	7.46	79.2	4.16	2.85	2.38	1.96
Dividend per share (in €)	1.26 ⁴	85.3	0.68	0.34	0.57	0.46
Balance sheet						
Balance sheet total	3,951.1	38.3	2,856.7	1,845.4	1,571.5	1,403.9
Equity	1,733.2	18.6	1,461.0	1,188.9	1,044.9	879.5
Equity ratio (in %)	43.9	-7.2pp	51.1	64.4	66.5	62.6
Financials						
Capital expenditures as % of sales revenue	11.2	2.9pp	8.3	9.4	14.6	12.6
Depreciation and amortization	141.5	41.1	100.3	72.8	60.9	50.6
Cash flow from operating activities	696.0	66.9	416.9	310.1	227.3	174.7
Net debt ⁵	401.9	-23.8	527.3	110.4	125.7	127.1
Ratio of net debt to underlying EBITDA ^{1,2,6}	0.4		0.8	0.3	0.4	0.4
Total number of employees as of December 31	10,409	37.6	7,566	6,223	5,637	5,092

1 Adjusted for extraordinary items

2 For more information on EBITDA, net profit and the underlying presentation, please refer to the Group Business Development chapter and to the Glossary.

3 Adjusted for extraordinary items, non-cash amortization acc. to IFRS 3 and fair value adjustments of hedging instruments, as well as the corresponding tax effects for each of these items.

4 Amount suggested by the Board of Directors (Conseil d'administration) and subject to approval by the Annual General Shareholders' Meeting.

5 Net debt excludes the liability for the remaining purchase price for acquisitions; 2021: €518.7 million, 2020: €127.8 million, 2019: €72.5 million, 2018: €8.7 million, 2017: €46.5 million

6 EBITDA includes underlying pro forma EBITDA contributed by acquisitions for this period

7 The figures for the reporting period 2020 were restated due to the finalization of the purchase price allocation for the acquisitions of BIA Separations and WaterSep BioSeparations

Sartorius Stedim Biotech Share in Comparison to the CAC Large 60 (indexed)

